Table 1. Numbers of 1975-1999 Approvals for Neglected Diseases.
Disease Category | Trouiller et al. new chemical entities (NCEs) targeting “tropical diseases” and tuberculosis | Our Analysis | ||
Our recount of Trouiller et al. NCEs | Our tally of G-Finder defined drugs targeting neglected diseases | Our tally of G-Finder defined indications targeting neglected diseases | ||
HIV/AIDS* | n/a** | n/a** | 6*** | 6 |
Malaria | 4 | 7 | 7 | 7 |
Tuberculosis | 3 | 12 | 12 | 12 |
Bacterial Pneumonia and Meningitis | n/a** | n/a** | 3 | 3 |
Diarrheal Diseases | n/a** | n/a** | 2 | 4 |
Kinetoplastids | 5 | 2 | 2 | 2 |
Buruli Ulcer | n/a** | 0 | 0 | 1 |
Dengue Fever | 0 | 0 | 0 | 0 |
Helminths | 4 | 9 | 9 | 16 |
Leprosy | 0 | 2 | 2 | 2 |
Trachoma | n/a** | n/a** | 1 | 1 |
Rheumatic Fever | n/a** | n/a** | 1 | 1 |
Typhoid and Paratyphoid Fever | n/a** | n/a** | 1 | 1 |
Total Approvals | 16 | 32 | 46 | 56 |
Percentage on Essential Drug List | 94% | 85% | 85% | 82% |
*In their analysis, Trouiller et al. included 26 HIV drugs-20 anti-virals and 6 drugs for “opportunistic diseases”-but as a separate (non-neglected) disease category.
**Disease categories Trouiller et al. did not include in their analysis.
***HIV/AIDS drugs with applications specific to the developing world, such as vaccines, microbicides and pediatric label extensions. Sources: PharmaProjects, IMS R&D Focus, http://www.accessdata.fda.gov/Scripts/cder/DrugsatFDA, http://eudrapharm.eu/eudrapharm/searchbykeyword.do, http://www.cbg-meb.nl/CBG/en/human-medicines/actueel, http://www.pharmacyboardkenya.org/index.php?id=13&dpgndg1=42&an=, http://www.who.int/medicines/publications/08_ENGLISH_indexFINAL_EML15.pdf, http://www.cdsco.nic.in/, http://www.afssaps.fr/, http://www.mhra.gov.uk/index.htm, http://www.bmg.bund.de.